XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Changes in Redeemable Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
Series A
Redeemable, Convertible Preferred Stock
Series B
Redeemable, Convertible Preferred Stock
Series C
Redeemable, Convertible Preferred Stock
Series D
Redeemable, Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2020 $ 1,077,303 $ 1,800,347 $ 1,000,465 $ 315 $ (4,206,488) $ (4,206,173)
Balance (in Shares) at Dec. 31, 2020 10,600 5,187 636   3,147,200      
Exercise of common stock warrants $ 471 140,990 141,461
Exercise of common stock warrants (in Shares)         4,715,836      
Accretion of redeemable, convertible preferred stock to redemption value 73,912 33,994 19,961 (127,866) (127,866)
Conversion of convertible debentures into Series D preferred stock $ 4,036,535
Conversion of convertible debentures into Series D preferred stock (in Shares)       4,500        
Conversion of redeemable, convertible preferred stock into common stock $ (1,151,215) $ (1,834,341) $ (1,020,426) $ (4,036,535) $ 708 8,041,809 8,042,517
Conversion of redeemable, convertible preferred stock into common stock (in Shares) (10,600) (5,187) (636) (4,500) 7,084,323      
Fair value of warrants issued for services 180,339 180,339
Fair value of warrants issued to placement agent in relation to the Convertible debentures 166,816 166,816
Conversion of Amended 2017 Convertible Notes into common stock $ 58 579,942 580,000
Conversion of Amended 2017 Convertible Notes into common stock (in Shares)         580,000      
Reclassification of Series B Warrants 145,953 145,953
Stock-based compensation expense 68,458 68,458
Issuance of common stock from exercise of stock options $ 6 22,617 22,623
Issuance of common stock from exercise of stock options (in Shares)         56,385      
Issuance of common stock in initial public offering, net of offering costs of $2,750,601 $ 216 18,855,663 18,855,879
Issuance of common stock in initial public offering, net of offering costs of $2,750,601 (in Shares)         2,160,000      
Issuance of common stock from exercise of warrants $ 237 (237)
Issuance of common stock from exercise of warrants (in Shares)         2,368,500      
Net loss (3,488,298) (3,488,298)
Balance at Dec. 31, 2021 $ 2,011 28,074,484 (7,694,786) 20,381,709
Balance (in Shares) at Dec. 31, 2021         20,112,244      
Impact of adoption of ASC 842 (5,368) (5,368)
Impact of adoption of ASC 842 (in Shares)              
Stock-based compensation expense 433,004 433,004
Stock-based compensation expense (in Shares)              
Exercise of stock options $ 7 28,869 28,876
Exercise of stock options (in Shares)         62,944      
Exercise of common stock Series B Warrants $ 4 (4)
Exercise of common stock Series B Warrants (in Shares)         40,100      
Net loss (9,296,948) (9,296,948)
Balance at Dec. 31, 2022 $ 2,022 $ 28,536,353 $ (16,997,102) $ 11,541,273
Balance (in Shares) at Dec. 31, 2022         20,215,288